On Nov 08, major Wall Street analysts update their ratings for $Sarepta Therapeutics (SRPT.US)$, with price targets ranging from $150 to $209.
Morgan Stanley analyst Michael Ulz maintains with a buy rating, and maintains the target price at $200.
Barclays analyst Gena Wang maintains with a buy rating, and maintains the target price at $209.
Evercore analyst Gavin Clark-Gartner maintains with a buy rating, and adjusts the target price from $179 to $170.
TD Cowen analyst Ritu Baral maintains with a buy rating, and maintains the target price at $203.
Guggenheim analyst Debjit Chattopadhyay maintains with a buy rating, and sets the target price at $150.
Furthermore, according to the comprehensive report, the opinions of $Sarepta Therapeutics (SRPT.US)$'s main analysts recently are as follows:
Sarepta reported significant third-quarter earnings, surpassing expectations for both total and Elevidys revenue. Analyst commentary suggests that Sarepta's consistent guidance for Elevidys may seem understated.
Sales of Elevidys and the exon-skipping franchise exceeded expectations, and the management's forecast for Q4 Elevidys remains steady, suggesting the possibility of surpassing predictions provided holiday disruptions remain low. There is a potential for a positive adjustment to the full-year guidance for 2025 come January, yet the current market valuation seems to reflect a five-year trajectory toward the end of exclusivity.
Sales of Elevidys experienced better-than-anticipated growth in the third quarter, accompanied by optimistic commentary from management regarding the product's launch. Analysts believe that all indications suggest the potential for Elevidys to become a multi-billion-dollar product, with the prospects of being augmented by a series of gene therapy introductions in the upcoming five years.
Here are the latest investment ratings and price targets for $Sarepta Therapeutics (SRPT.US)$ from 9 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月8日，多家华尔街大行更新了$Sarepta Therapeutics (SRPT.US)$的评级，目标价介于150美元至209美元。
摩根士丹利分析师Michael Ulz维持买入评级，维持目标价200美元。
巴克莱银行分析师Gena Wang维持买入评级，维持目标价209美元。
Evercore分析师Gavin Clark-Gartner维持买入评级，并将目标价从179美元下调至170美元。
TD Cowen分析师Ritu Baral维持买入评级，维持目标价203美元。
Guggenheim分析师Debjit Chattopadhyay维持买入评级，目标价150美元。
此外，综合报道，$Sarepta Therapeutics (SRPT.US)$近期主要分析师观点如下：
Sarepta报告了第三季度显著的营收，超出了对于总营业收入和Elevidys营收的预期。分析师评论表明，Sarepta对于Elevidys的一贯指导可能显得有所保守。
Elevidys和外显子跳跃特许经营的销售超出了预期，管理层对于第四季度Elevidys的预测保持稳定，这表明在提供节日干扰保持较低的情况下，有可能超出预期。到了一月份，有可能会对2025年全年指引进行积极调整，然而当前市场估值似乎反映了未来五年通向专有结束的轨迹。
Elevidys在第三季度经历了比预期更好的增长，伴随着管理层在产品推出方面的乐观评论。分析师们认为，所有迹象表明Elevidys有成为一个价值数十亿美元的产品的潜力，并且未来五年可能会因一系列基因治疗的引入而增值。
以下为今日9位分析师对$Sarepta Therapeutics (SRPT.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
